Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase |
| |
Authors: | J. Nuutila S. Kaakkola P. T. MÄnnistö |
| |
Affiliation: | (1) Research Center, Orion Pharmaceutical Co., Espoo;(2) Present address: Department of Pharmacology and Toxicology, University of Helsinki, Finland |
| |
Abstract: | Summary The effects of a COMT-inhibitor, U-0521, and a MAO-B-inhibitor, l-deprenyl, on L-dopa-induced circling behaviour were compared in 6-OHDA-lesioned rats. The actions of U-0521 and l-deprenyl on the anticataleptic effect of L-dopa were also studied. Both U-0521 and l-deprenyl were found to potentiate L-dopa-induced circling behaviour and anticataleptic effect of L-dopa. In both test systems the L-dopa potentiation of l-deprenyl was longer-lasting than that caused by U-0521. Thus inhibition of COMT, like inhibition of MAO, is able to enhance the central effects of L-dopa. This principle might be beneficial in the treatment of Parkinson's disease especially if COMT-inhibitors with greater performance can be developed. |
| |
Keywords: | Catechol-O-methyltransferase (COMT) inhibitors l-deprenyl (selegilin) L-dopa Parkinson's disease, animal models U-0521 (3 /content/u3wkt799601w1j82/xxlarge8242.gif" alt=" prime" align=" BASELINE" BORDER=" 0" >, 4 /content/u3wkt799601w1j82/xxlarge8242.gif" alt=" prime" align=" BASELINE" BORDER=" 0" >-dihydroxy-2-methylpropiophenone) |
本文献已被 SpringerLink 等数据库收录! |
|